Long COVID — post-acute sequelae of COVID-19 (PASC) — affects an estimated 15–20% of SARS-CoV-2 infections, with 1.3 million Americans currently reporting post-COVID symptoms limiting daily activities (US Census Bureau Household Pulse Survey, 2024). Despite 4+ years of research, the mechanistic heterogeneity of Long COVID and absence of approved treatments makes clinical management challenging — though the evidence base for specific symptom clusters has grown substantially.
Proposed Mechanisms (Not Mutually Exclusive)
Long COVID is likely a syndrome with multiple overlapping mechanisms rather than a single disease entity: (1) Viral reservoir/persistence: SARS-CoV-2 RNA and antigen detected in gut, lymph nodes, and multiple tissues months post-acute infection — microglial activation in brain tissue of Long COVID patients (2023 Nature, autopsy data). This is currently the leading mechanistic hypothesis and the target of ongoing antiviral trials (Paxlovid extended-course trials). (2) Autoimmunity: autoantibodies against ACE2, adrenergic receptors, muscarinic receptors, and other self-antigens detected in subset of Long COVID patients — potentially explaining dysautonomia and symptom heterogeneity. (3) Microbiome disruption: COVID-19 dramatically disrupts gut microbiome diversity; dysbiosis correlates with Long COVID symptom burden in prospective cohort studies. (4) Reactivation of latent viruses: EBV, HHV-6, and CMV reactivation detected in Long COVID patients — may contribute to symptom burden through immune activation. (5) Microclot formation: fibrin amyloid microclots detected in Long COVID blood samples — may cause tissue hypoperfusion.
Evidence-Based Symptom Management
Post-exertional malaise (PEM) — the most diagnostically specific Long COVID symptom (also characteristic of ME/CFS): aggressive pacing (staying within individual "energy envelope") is the evidence-based cornerstone — pacing reduces symptom exacerbation. Graded exercise therapy (GET) is contraindicated for PEM-positive patients — multiple studies show GET worsens outcomes in this population. NICE guidelines explicitly contraindicate GET for post-COVID PEM. Cognitive dysfunction ("brain fog"): neuropsychological rehabilitation with pacing, cognitive aids, and activity restructuring — pharmacological trials ongoing (guanfacine + NAC pilot showing improvement). Dysautonomia/POTS: increased salt and fluid intake (10g Na/day, 3L/day fluid), compression garments, progressive low-intensity recumbent exercise (avoid upright exercise initially), beta-blockers (propranolol) or ivabradine for HR control. Current clinical trials of note: RECOVER-VITAL (Paxlovid extended course), RECOVER-NEURO (cognitive rehabilitation platform), and multiple immunomodulatory trials (low-dose naltrexone, BC007 anti-autoantibody treatment). For clinical settings managing Long COVID patients, our diagnostic equipment catalog includes pulse oximeters and blood pressure monitors for dysautonomia monitoring, and our wound care supplies support comprehensive chronic condition management.
